WO2021182900A3 - Procédé de prévention ou de traitement de maladies associées à mtor par la régulation de l'expression de vegfr -3 - Google Patents

Procédé de prévention ou de traitement de maladies associées à mtor par la régulation de l'expression de vegfr -3 Download PDF

Info

Publication number
WO2021182900A3
WO2021182900A3 PCT/KR2021/003051 KR2021003051W WO2021182900A3 WO 2021182900 A3 WO2021182900 A3 WO 2021182900A3 KR 2021003051 W KR2021003051 W KR 2021003051W WO 2021182900 A3 WO2021182900 A3 WO 2021182900A3
Authority
WO
WIPO (PCT)
Prior art keywords
mtor
vegfr
regulation
preventing
present
Prior art date
Application number
PCT/KR2021/003051
Other languages
English (en)
Korean (ko)
Other versions
WO2021182900A2 (fr
Inventor
김원주
정경훈
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2021182900A2 publication Critical patent/WO2021182900A2/fr
Publication of WO2021182900A3 publication Critical patent/WO2021182900A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)

Abstract

La présente invention concerne une composition destinée à prévenir ou à traiter une cible mammifère de maladies médiées par la rapamycine (mTOR) et des maladies associées à une signalisation de mTOR déficiente. La présente invention concerne une cible thérapeutique efficace pour diverses maladies provoquées par une hyperactivité ou une activité déficiente de mTOR, sur la base de la nouvelle découverte que la régulation de l'expression de VEGFR -3 conduit à la régulation de l'activité de la voie de signalisation de mTOR. La présente invention, en particulier par activation de VEGFR -3, bloque les états hyperexcitatifs de l'épilepsie et protège les nerfs et peut ainsi être efficacement utilisée en tant qu'agent thérapeutique fondamental pour l'état épileptique, qui est une maladie incurable.
PCT/KR2021/003051 2020-03-11 2021-03-11 Procédé de prévention ou de traitement de maladies associées à mtor par la régulation de l'expression de vegfr -3 WO2021182900A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200030038A KR102371269B1 (ko) 2020-03-11 2020-03-11 VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법
KR10-2020-0030038 2020-03-11

Publications (2)

Publication Number Publication Date
WO2021182900A2 WO2021182900A2 (fr) 2021-09-16
WO2021182900A3 true WO2021182900A3 (fr) 2021-11-04

Family

ID=77671857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/003051 WO2021182900A2 (fr) 2020-03-11 2021-03-11 Procédé de prévention ou de traitement de maladies associées à mtor par la régulation de l'expression de vegfr -3

Country Status (2)

Country Link
KR (1) KR102371269B1 (fr)
WO (1) WO2021182900A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030094395A (ko) * 2001-05-08 2003-12-11 쉐링 악티엔게젤샤프트 Ｖｅｇｆｒ-2 및 ｖｅｇｆｒ-3의 억제제로서의 선택적안트라닐아미드 피리딘 아미드
KR20100135754A (ko) * 2008-02-21 2010-12-27 아스트라제네카 아베 병용 요법 238
WO2014022879A1 (fr) * 2012-08-06 2014-02-13 Pitney Pharmaceuticals Pty Limited Composés pour le traitement de maladies associées à la voie mtor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
KR20180120476A (ko) * 2017-04-27 2018-11-06 가톨릭대학교 산학협력단 Vegfr3 억제제를 유효성분으로 포함하는 당뇨병성 미세혈관 합병증의 예방 또는 치료용 약학 조성물
JP2019184237A (ja) * 2018-03-30 2019-10-24 学校法人 岩手医科大学 急性肺傷害治療剤のスクリーニング方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030094395A (ko) * 2001-05-08 2003-12-11 쉐링 악티엔게젤샤프트 Ｖｅｇｆｒ-2 및 ｖｅｇｆｒ-3의 억제제로서의 선택적안트라닐아미드 피리딘 아미드
KR20100135754A (ko) * 2008-02-21 2010-12-27 아스트라제네카 아베 병용 요법 238
WO2014022879A1 (fr) * 2012-08-06 2014-02-13 Pitney Pharmaceuticals Pty Limited Composés pour le traitement de maladies associées à la voie mtor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KYOUNG HOON JEONG,KYUNG-OK CHO,MUN-YONG LEE,SEONG YUN KIM,WON-JOO KIM: "Vascular endothelial growth factor receptor-3 regulates astroglial glutamate transporter-1 expression via mTOR activation in reactive astrocytes following pilocarpine-induced status epilepticus", GLIA, vol. 69, no. 2, 1 February 2021 (2021-02-01), US, pages 296 - 309, XP055862401, ISSN: 0894-1491, DOI: 10.1002/glia.23897 *
LUO YAN, LIU LEI, ROGERS DONNA, SU WEI, ODAKA YOSHINOBU, ZHOU HONGYU, CHEN WENXING, SHEN TAO, ALEXANDER J. STEVEN, HUANG SHILE: "Rapamycin Inhibits Lymphatic Endothelial Cell Tube Formation by Downregulating Vascular Endothelial Growth Factor Receptor 3 Protein Expression", NEOPLASIA, vol. 14, no. 3, 1 March 2012 (2012-03-01), pages 228 - 237, XP055862397, ISSN: 1476-5586, DOI: 10.1593/neo.111570 *
XINGMEI FENG,DAN HUANG,XIAOHUI LU,GUIJUAN FENG,JING XING,JUN LU,KE XU,WEIWEI XIA,YAN MENG,TAO TAO,LIREN LI,ZHIFENG GU: "Insulin-like growth factor 1 can promote proliferation and osteogenic differentiation of human dental pulp stem cells via mTOR pathway", DEVELOPMENT, GROWTH & DIFFERENTIATION, vol. 56, no. 9, 1 December 2014 (2014-12-01), US, pages 615 - 624, XP055862398, ISSN: 0012-1592, DOI: 10.1111/dgd.12179 *

Also Published As

Publication number Publication date
KR102371269B1 (ko) 2022-03-07
WO2021182900A2 (fr) 2021-09-16
KR20210114661A (ko) 2021-09-24

Similar Documents

Publication Publication Date Title
MX2022001296A (es) Inhibidores de kif18a.
WO2020163823A3 (fr) Agents thérapeutiques et méthodes de traitement
WO2021252538A3 (fr) Compositions de benzofurane avantageuses pour troubles mentaux ou amélioration mentale
WO2005117882A8 (fr) Derives d'acide hydroxamique en tant qu'inhibiteurs de metalloproteases
GEP20094705B (en) Aza spiro alkane derivatives as inhibitors of metalloproteases
MX2022014966A (es) D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso.
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
MX2022006807A (es) Análogos de rapamicina y usos de estos.
WO2006052926A3 (fr) Tweak comme cible therapeutique permettant de traiter les maladies du systeme nerveux central associees a un oedeme cerebral et a une mort cellulaire
WO2021236779A9 (fr) Compositions et procédés pour moduler l'activité de la déshydrogénase à chaîne courte
Möller et al. Impact of repeated kindled seizures on heart rate rhythms, heart rate variability, and locomotor activity in rats
WO2021182900A3 (fr) Procédé de prévention ou de traitement de maladies associées à mtor par la régulation de l'expression de vegfr -3
MX2022014925A (es) Moduladores de il-17a.
WO2022020522A3 (fr) Modulateurs de mtorc1 et leurs utilisations
WO2021142448A3 (fr) Inhibiteurs de tgf-bêta et leur utilisation
MX2019011000A (es) Derivados de pirazolo [1,5-a]pirimidina aliciclicos-sustituidos farmacologicamente activos.
WO2004016214A3 (fr) Methodes et compositions de traitement de troubles maculaires et retinaux
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
DE602004032165D1 (de) Nervenregenerationsförderer
WO2001080845A3 (fr) Substances et méthodes de traitement de la dépression
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.
MX2021011575A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
WO2023183613A3 (fr) Composés d'indolizine pour le traitement de troubles mentaux ou d'une inflammation
WO2023225563A3 (fr) Ligands sélectifs du récepteur sigma-2 en tant que modulateurs de tmem97
MX2022001567A (es) Compuestos inhibidores de histona desacetilasa (ihdac) derivados de acidos hidroxamicos y su uso como agentes para el tratamiento de gliomas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21768376

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21768376

Country of ref document: EP

Kind code of ref document: A2